BR112022011906A2 - Peptídeos retro-inversos - Google Patents
Peptídeos retro-inversosInfo
- Publication number
- BR112022011906A2 BR112022011906A2 BR112022011906A BR112022011906A BR112022011906A2 BR 112022011906 A2 BR112022011906 A2 BR 112022011906A2 BR 112022011906 A BR112022011906 A BR 112022011906A BR 112022011906 A BR112022011906 A BR 112022011906A BR 112022011906 A2 BR112022011906 A2 BR 112022011906A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- diseases
- retro
- description
- disorders
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 238000003874 inverse correlation nuclear magnetic resonance spectroscopy Methods 0.000 title abstract 2
- 208000017667 Chronic Disease Diseases 0.000 abstract 2
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 2
- 208000024556 Mendelian disease Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003412 degenerative effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000037821 progressive disease Diseases 0.000 abstract 2
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108091005601 modified peptides Proteins 0.000 abstract 1
- 239000003900 neurotrophic factor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
PEPTÍDEOS RETRO-INVERSOS. A presente descrição refere-se ao campo de fatores neurotróficos não convencionais e ao campo de tratamento de doenças e distúrbios degenerativos, crônicos ou progressivos e doenças hereditárias monogênicas com estresse de RE como um composto patogênico. Mais particularmente, a descrição refere-se a peptídeos modificados, particularmente peptídeos retro-inversos. A descrição também se refere a composições farmacêuticas compreendendo os ditos peptídeos. Além disso, a descrição também se refere aos ditos peptídeos e composições farmacêuticas para uso como um medicamento e no tratamento de doenças e distúrbios degenerativos, crônicos ou progressivos e doenças hereditárias monogênicas com estresse de RE como um composto patogênico, bem como a métodos para tratar as ditas doenças e distúrbios.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19218611.2A EP3838912A1 (en) | 2019-12-20 | 2019-12-20 | Retro-inverso peptides |
| PCT/EP2020/086868 WO2021123050A1 (en) | 2019-12-20 | 2020-12-17 | Retro-inverso peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011906A2 true BR112022011906A2 (pt) | 2022-09-06 |
Family
ID=69061067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011906A BR112022011906A2 (pt) | 2019-12-20 | 2020-12-17 | Peptídeos retro-inversos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230391842A1 (pt) |
| EP (2) | EP3838912A1 (pt) |
| JP (1) | JP2023509383A (pt) |
| KR (1) | KR20220117319A (pt) |
| CN (1) | CN114846020B (pt) |
| AU (1) | AU2020409569A1 (pt) |
| BR (1) | BR112022011906A2 (pt) |
| CA (1) | CA3165091A1 (pt) |
| WO (1) | WO2021123050A1 (pt) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE102006004612A1 (de) * | 2006-02-01 | 2007-08-16 | Ralf Dr. med. Jochem | Therapeutische Zusammensetzung zur Vorbeugung und Bekämpfung von Knochenmetastasen |
| ATE480559T1 (de) | 2005-12-14 | 2010-09-15 | Licentia Ltd | Verwendungen eines neurotrophischen faktors |
| CN102083456B (zh) * | 2008-03-25 | 2015-12-02 | 阿姆拉特斯治疗公司 | 神经退行性障碍 |
| FI20080326A0 (fi) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
| US8906355B2 (en) * | 2009-10-29 | 2014-12-09 | Lucia Irene Gonzalez | Synthetic stereoisomer peptides in the retro-inverso and inverso configuration, and with cyclic and linear structure, their polymer conjugates, their encapsulation in polymer particles, and uses thereof |
| ES2594605T3 (es) * | 2011-06-09 | 2016-12-21 | University Of Miami | Factores neurotróficos MANF y CDNF para uso en el tratamiento de trastornos de la retina |
| FI20115870A0 (fi) | 2011-09-05 | 2011-09-05 | Urmas Arumaee | Neuroprotektiiviset soluihin tunkeutuvat peptidit |
| US9421245B2 (en) * | 2012-06-25 | 2016-08-23 | The Brigham And Women's Hospital, Inc. | Targeted therapeutics |
| EP3377089B1 (en) * | 2015-11-18 | 2020-04-08 | Herantis Pharma Plc | Compositions comprising cdnf for use in the intranasal treatment of central nervous system diseases |
| CA3063061A1 (en) * | 2016-05-12 | 2017-11-16 | Ohio State Innovation Foundation | Peptides and methods for treating neurodegenerative disorders |
| MX2019013157A (es) | 2017-05-04 | 2020-08-03 | Helsingin Yliopisto | Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. |
-
2019
- 2019-12-20 EP EP19218611.2A patent/EP3838912A1/en not_active Withdrawn
-
2020
- 2020-12-17 WO PCT/EP2020/086868 patent/WO2021123050A1/en active Search and Examination
- 2020-12-17 US US17/757,402 patent/US20230391842A1/en active Pending
- 2020-12-17 KR KR1020227025155A patent/KR20220117319A/ko unknown
- 2020-12-17 CA CA3165091A patent/CA3165091A1/en active Pending
- 2020-12-17 EP EP20842212.1A patent/EP4077348A1/en active Pending
- 2020-12-17 CN CN202080088948.0A patent/CN114846020B/zh active Active
- 2020-12-17 BR BR112022011906A patent/BR112022011906A2/pt unknown
- 2020-12-17 AU AU2020409569A patent/AU2020409569A1/en active Pending
- 2020-12-17 JP JP2022538266A patent/JP2023509383A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3838912A1 (en) | 2021-06-23 |
| CN114846020B (zh) | 2024-09-13 |
| US20230391842A1 (en) | 2023-12-07 |
| WO2021123050A1 (en) | 2021-06-24 |
| CA3165091A1 (en) | 2021-06-24 |
| KR20220117319A (ko) | 2022-08-23 |
| JP2023509383A (ja) | 2023-03-08 |
| CN114846020A (zh) | 2022-08-02 |
| EP4077348A1 (en) | 2022-10-26 |
| AU2020409569A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010349A2 (pt) | Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma | |
| AU2016219611A1 (en) | Compositions comprising mixtures of semifluorinated alkanes | |
| BR112018070859A2 (pt) | degradantes da proteína de bet | |
| BR112018010018A2 (pt) | moduladores de ror-gama | |
| BR112018015273A2 (pt) | derivados de benzimidazol como moduladores de ror-gama | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| BR112015020389A8 (pt) | compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos | |
| BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
| BR112015027319A8 (pt) | Métodos e composições para modular a expressão de apolipoproteína (a) | |
| BR112015011403A2 (pt) | uso de akkermansia para o tratamento de distúrbios metabólicos | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| BR112015024678A2 (pt) | inibidor da cinase | |
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| BR112019006463A2 (pt) | composição oral de canabinoides extraídos e métodos de uso da mesma | |
| BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
| WO2018111315A8 (en) | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
| BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
| BR112017022757A2 (pt) | derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap) | |
| BR112017024727A2 (pt) | cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g |